Bladder cancer biomarkers: current developments and future implementation
Authors:
- Vinata B LokeshwarVLVinata B Lokeshwar
- 1 September 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 17 (5) , 341-346
Abstract
Bladder cancer biomarker development has advanced significantly over the last decade, but has not yet been able to make a significant impact in the diagnosis and management of the disease. Many available markers are suitable, but do not meet the expectations of physicians and patients. Patients do not want to compromise accuracy in diagnosing bladder cancer for less-invasive tests. The review highlights the latest developments in bladder cancer biomarkers, including markers developed over the last year, and comments on the high standards placed on these markers which have delayed their widespread implementation into the urologic field. New markers described in the last year include soluble Fas, urothelial carcinoma-associated 1 and human chorionic gonadotropin β type II genes. The latter two markers represent the contribution of genomic technology to this field. Also described are updates to known markers, including long-term follow-up of hematuria screening, recent studies in DNA methylation for bladder cancer diagnosis and patient perspectives on bladder tumor markers. Biomarkers for bladder cancer have been intensively scrutinized over the last decade, but despite new findings and good performance characteristics, they are currently not accepted in clinical practice.Keywords
This publication has 58 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Muscle-Invasive Urothelial Carcinoma of the BladderUrology, 2007
- Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial CancerJournal of Clinical Oncology, 2006
- Urinary bladder tumor markersUrologic Oncology: Seminars and Original Investigations, 2006
- Long‐term outcome of hematuria home screening for bladder cancer in menCancer, 2006
- Comparison of NMP22 BladderChek Test and Urine Cytology for the Detection of Recurrent Bladder CancerJapanese Journal of Clinical Oncology, 2006
- Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic AssayJAMA, 2006
- Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markersUrology, 2005
- The health economics of bladder cancerPharmacoEconomics, 2003
- Urinary tract cancer screening through analysis of urinary red blood cell volume distributionInternational Journal of Urology, 2000